Home > Insider Trading > Filing (0001576280-21-000108)

Filing Details

Accession Number:: 0001576280-21-000108
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-23 19:07:02
Reporting Period:: 2021-11-19

Accepted Time:: 2021-11-23 19:07:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576280	Guardant Health Inc.	GH	Services-Medical Laboratories (8071)	454139254

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753159	Amirali Talasaz	505 Penobscot Drive Redwood City CA 94063	Co-Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-11-19	37,721	$97.82	1,787,066	No	4	P	Direct
Common Stock	Acquisiton	2021-11-19	12,279	$98.78	1,799,345	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	6,033	$92.42	1,805,378	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	23,467	$93.05	1,828,845	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	5,000	$94.00	1,833,845	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	5,000	$95.50	1,838,845	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	14,900	$96.83	1,853,745	No	4	P	Direct
Common Stock	Acquisiton	2021-11-23	100	$98.00	1,853,845	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	470,800	Indirect	Shares held by Talasaz Investments, L.P.

Footnotes

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.64 to $98.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.75 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.885 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.915 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.